 NEW YORK, June 3, 2021 PRNewswire -- Actinium Pharmaceuticals, Inc. NYSE AMERICAN: ATNM Actinium or the Company today announced that three abstracts highlighting data and findings from the Companys pivotal Phase 3 SIERRA trial for lead program Iomab-B, have been accepted for 2 oral and 2 poster presentations at the Society of Nuclear Medicine and Molecular Imaging SNMMI 2021 Annual Meeting, which is being held virtually June 11 14, 2021. Coinciding with SNMMI, Actinium will be hosting two Iomab-B advisory board meetings with nuclear medicine physicians, technicians, pharmacists, and physicists. 